In Section A, contributors will receive different doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Supplemental participants might be enrolled in the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, participants https://abbv-744-safety-and-side46679.blogsuperapp.com/32550045/top-latest-five-brd4-targeted-therapy-abbv-744-clinical-data-urban-news